Skip to main content

Table 4 Comparing occurrences of hematological and non-hematological AEs between the propensity score matched treatment groups

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Treatment comparison

Platinum/Pemetrexed vs. Platinum/Docetaxel

  

Platinum/Pemetrexed vs. Platinum/Paclitaxel

  

Platinum/Pemetrexed vs. Platinum/Gemcitabine

  

Platinum/Pemetrexed vs. Platinum/Vinorelbine

  

Matched pairs

95

RR

P value*

118

RR

P value*

199

RR

P value*

72

RR

P value*

All grades AE

N

%

N

%

  

N

%

N

%

  

N

%

N

%

  

N

%

N

%

  

Hematological AE

                        

Leukopenia

29

30.5%

27

28.4%

1.074

0.752

34

28.8%

39

33.1%

0.872

0.508

64

32.2%

84

42.2%

0.762

0.041

18

25.0%

27

37.5%

0.667

0.106

Neutropenia

24

25.3%

19

20.0%

1.263

0.336

29

24.6%

35

29.7%

0.829

0.396

63

31.7%

57

28.6%

1.105

0.540

12

16.7%

23

31.9%

0.522

0.034

Thrombocytopenia

24

25.3%

24

25.3%

1.000

1.000

32

27.1%

34

28.8%

0.941

0.773

59

29.6%

100

50.3%

0.590

<0.001

25

34.7%

26

36.1%

0.962

0.876

Anemia

34

35.8%

31

32.6%

1.097

0.647

46

39.0%

53

44.9%

0.868

0.370

87

43.7%

125

62.8%

0.696

<0.001

35

48.6%

46

63.9%

0.761

0.063

Any hematological AE

56

58.9%

58

61.1%

0.966

0.752

70

59.3%

80

67.8%

0.875

0.189

130

65.3%

163

81.9%

0.798

<0.001

47

65.3%

58

80.6%

0.810

0.056

Non-hematological AE

                   

0.0%

 

0.0%

  

Alopecia

3

3.2%

15

15.8%

0.200

0.005

1

0.8%

8

6.8%

0.125

0.020

2

1.0%

18

9.0%

0.111

<0.001

0

0.0%

1

1.4%

0.000

1.000

Arthralgia

5

5.3%

4

4.2%

1.250

0.706

0

0.0%

0

0.0%

—

—

2

1.0%

8

4.0%

0.250

0.058

0

0.0%

0

0.0%

—

—

Cough

1

1.1%

2

2.1%

0.500

0.564

1

0.8%

1

0.8%

1.000

1.000

3

1.5%

12

6.0%

0.250

0.020

2

2.8%

1

1.4%

2.000

0.564

Dermatitis

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

Diarrhea

1

1.1%

2

2.1%

0.500

0.317

1

0.8%

0

0.0%

—

1.000

3

1.5%

0

0.0%

—

0.250

2

2.8%

3

4.2%

0.667

0.655

Dyspnea

1

1.1%

0

0.0%

—

1.000

1

0.8%

0

0.0%

—

1.000

3

1.5%

6

3.0%

0.500

0.317

1

1.4%

0

0.0%

—

1.000

Edema

1

1.1%

0

0.0%

—

1.000

1

0.8%

0

0.0%

—

1.000

3

1.5%

1

0.5%

3.000

0.317

1

1.4%

0

0.0%

—

1.000

Fatigue

11

11.6%

11

11.6%

1.000

1.000

10

8.5%

27

22.9%

0.370

0.001

18

9.0%

62

31.2%

0.290

<0.001

13

18.1%

23

31.9%

0.565

0.048

Nausea

63

66.3%

67

70.5%

0.940

0.527

78

66.1%

84

71.2%

0.929

0.446

134

67.3%

148

74.4%

0.905

0.122

53

73.6%

53

73.6%

1.000

1.000

Peripheral neuropathy

1

1.1%

3

3.2%

0.333

0.317

0

0.0%

5

4.2%

0.000

0.063

3

1.5%

2

1.0%

1.500

0.657

1

1.4%

2

2.8%

0.500

0.564

Rash

2

2.1%

0

0.0%

—

0.500

2

1.7%

0

0.0%

—

0.500

5

2.5%

5

2.5%

1.000

1.000

1

1.4%

0

0.0%

—

1.000

Stomatitis

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

0

0.0%

1

0.5%

0.000

1.000

0

0.0%

2

2.8%

0.000

0.500

Vomiting

40

42.1%

47

49.5%

0.851

0.286

51

43.2%

52

44.1%

0.981

0.895

92

46.2%

94

47.2%

0.979

0.849

31

43.1%

37

51.4%

0.838

0.366

Weight loss

0

0.0%

1

1.1%

0.000

1.000

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

0

0.0%

0

0.0%

—

—

  1. AE, adverse event; RR, rate ratio. *P values less than 0.05 were in bold to indicate significant differences.